Drugs / Methylselenocysteine
Methylselenocysteine
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04952129 | May 2022 → Dec 2023 | colorectal adenoma | University of Auckland, New Zealand | Completed | No outcome recorded |
| Phase 1 | NCT01497431 | Nov 2011 → Jun 2014 | prostate carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00489372 | Jul 2007 → Mar 2008 | — | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | methyl selenocysteine | “Se-methyl-seleno-L-cysteine (methyl selenocysteine; MSC)” NCT01497431 ↗ |
| Known as | Se-methyl-seleno-L-cysteine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00489372 ↗ |
| Known as | Se-methylselenocysteine | ChEMBL registry synonym — accepted as the source's own label CHEMBL62382 ↗ |
| Modality | Other / unclassified | “Seleno-amino acid” NCT04952129 ↗ |
| Route | Oral | “Given orally” NCT00489372 ↗ |